September 19, 2014 9:38 AM ET

Biotechnology

Company Overview of Nabi Biopharmaceuticals

Company Overview

As of October 30, 2012, Nabi Biopharmaceuticals was acquired by Biota Holdings Limited, in a reverse merger transaction. Nabi Biopharmaceuticals, a biopharmaceutical company, focuses on the development of vaccines for unmet medical needs, including nicotine addiction. The company engages in developing NicVAX, a proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. It has an option and licensing agreement with GlaxoSmithKline Biologicals S.A. to develop, commercialize, and manufacture NicVAX and follow-on nicotine addiction vaccines; a license agreement with National Institutes of Health to use rEPA carrier ...

12276 Wilkins Avenue

Rockville, MD 20852

United States

Founded in 1967

16 Employees

Phone:

301-770-3099

Fax:

301-770-3097

Key Executives for Nabi Biopharmaceuticals

Nabi Biopharmaceuticals does not have any Key Executives recorded.

Nabi Biopharmaceuticals Key Developments

Nabi Biopharmaceuticals Terminates Raafat Fahim as President and Chief Executive Officer

Nabi Biopharmaceuticals announced that in connection with the business combination transaction with Biota Holdings Limited, effective upon November 8, 2012, Raafat Fahim, Ph.D, was terminated as President and Chief Executive Officer of the company.

Nabi Biopharmaceuticals(NasdaqGS:BOTA) dropped from NASDAQ Composite Index

Nabi Biopharmaceuticals will be removed from NASDAQ Composite Index

Nabi Biopharmaceuticals Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2012

Nabi Biopharmaceuticals announced unaudited consolidated earnings results for the second quarter and six months ended September 30, 2012. For the quarter, the company reported revenue of $632,000 compared to $1,086,000 a year ago. Operating loss was $4,118,000 compared to $4,937,000 a year ago. Loss from continuing operations before income taxes was $4,090,000 compared to $4,922,000 a year ago. Loss from continuing operations was $4,090,000 or $0.12 per basic and diluted share compared to $2,904,000 or $0.07 per basic and diluted share a year ago. Net loss was $4,090,000 compared to net profit of $78,000 a year ago. For the six months, the company reported revenue of $1,895,000 compared to $14,003,000 a year ago. Operating loss was $9,156,000 compared to $7,753,000 a year ago. Loss from continuing operations before income taxes was $8,921,000 compared to $7,541,000 a year ago. Loss from continuing operations was $8,250,000 or $0.21 per basic and diluted share compared to $5,523,000 or $0.13 per basic and diluted share a year ago. Net loss was $7,259,000 compared to $2,541,000 a year ago. Net cash used in operating activities was $5,586,000 compared to $14,459,000 a year ago. The decrease in cash used is primarily due to a reduction in NicVAX-related clinical and manufacturing activities in 2012 as compared to 2011 and a reduction in overall operating costs.

Similar Private Companies By Industry

Company Name Region
Cytonome, Inc. United States
GX Healthcare LLC United States
California Stem Cell, Inc. United States
True North Therapeutics, Inc. United States
Itero Biopharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Nabi Biopharmaceuticals, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.